Aurobindo Pharma arm’s biosimilar gets Health Canada NOC
Aurobindo Pharma's subsidiary receives Health Canada NOC for Dyrupeg, confirming its pegylated filgrastim biosimilar's safety and efficacy.
9 Jan 17:31 · The Hindu
Aurobindo Pharma arm terminates biosimilar pact with U.S. firm BioFactura
Aurobindo Pharma subsidiary CuraTeQ Biologics and U.S. firm BioFactura have terminated their agreement relating to BFI-751, a proposed biosimilar to Janssen Biotech’s Stelara (Ustekinumab).
27 Dec 13:42 · The Hindu
last updated on 10 Jan 13:31